Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2022-03-07 02:49:10 UTC |
---|
HMDB ID | HMDB0001483 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Prostaglandin F2b |
---|
Description | Prostaglandin F2b is a naturally occurring isoprostane. Isoprostanes are arachidonic acid metabolites produced by peroxidative attack of membrane lipids. These accumulate to substantial levels in many clinical conditions characterized in part by accumulation of free radicals and reactive oxygen species, including asthma, hypertension and ischemia-reperfusion injury. For this reason, they are frequently used as markers of oxidative stress; however, many are now finding that these molecules are not inert, but in fact evoke powerful biological responses in an increasing array of cell types. In many cases, these biological effects can account in part for the various features and manifestations of those clinical conditions. Thus, it may be possible that the isoprostanes are playing somewhat of a causal role in those disease states. Lipid-peroxidation forms primary- or secondary-end products like conjugated dienes, lipid hydroperoxides, gaseous alkanes, and prostaglandin F2-like products. They are created as major products by free-radical catalyzed peroxidation of esterified arachidonic acid (AA) in membrane phospholipids. They are also minor products of the activity of platelet cyclooxygenase-1 (COX-1) in response to stimuli such as collagen, thrombin, or arachidonate. The levels of Prostaglandin F2b and F2-isoprostanes in CSF and urine are elevated in Alzheimer's disease (AD) patients when compared to that of age-matched controls. (PMID: 15275956 , 14504139 )Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
---|
Structure | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18+,19+/m0/s1 |
---|
Synonyms | Value | Source |
---|
5-Heptenoic acid, 7-[3,5-dihydroxy-2(3-hydroxy-1-octenyl)cyclopentyl]-, stereoisomer | ChEBI | 9beta,11alpha-PGF2a | ChEBI | 9beta,11alpha-PGF2alpha | ChEBI | PGF2b | ChEBI | PGF2beta | ChEBI | Prostaglandin F2-beta | ChEBI | 5-Heptenoate, 7-[3,5-dihydroxy-2(3-hydroxy-1-octenyl)cyclopentyl]-, stereoisomer | Generator | 9b,11a-PGF2a | Generator | 9Β,11α-PGF2a | Generator | 9Β,11α-PGF2α | Generator | PGF2Β | Generator | Prostaglandin F2-b | Generator | Prostaglandin F2-β | Generator | (5Z,13E)-9,11,15-Trihydroxy-prosta-5,13-dien-1-Oate | HMDB | (5Z,13E)-9,11,15-Trihydroxy-prosta-5,13-dien-1-Oic acid | HMDB | 7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoate | HMDB | 7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid | HMDB | 7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid stereoisomer | HMDB | 7-[3a,5b-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoate | HMDB | 7-[3a,5b-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid | HMDB | 9b,11a-PGF2 | HMDB | Prostaglandin F2beta | HMDB | Prostaglandin F2beta, (5Z,8beta,9beta,11alpha,12alpha,13E,15S)-isomer | HMDB | Prostaglandin F2beta, (5Z,9beta,11beta,13E,15S)-isomer | HMDB | Prostaglandin F2beta, (5Z,9beta,11beta,13E,15R)-isomer | HMDB | Prostaglandin F2b | ChEBI | Prostaglandin F2β | Generator |
|
---|
Chemical Formula | C20H34O5 |
---|
Average Molecular Weight | 354.481 |
---|
Monoisotopic Molecular Weight | 354.240624198 |
---|
IUPAC Name | (5Z)-7-[(1R,2R,3R,5R)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoic acid |
---|
Traditional Name | pgf(sub 2-β) |
---|
CAS Registry Number | 4510-16-1 |
---|
SMILES | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O |
---|
InChI Identifier | InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18+,19+/m0/s1 |
---|
InChI Key | PXGPLTODNUVGFL-JZFBHDEDSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Eicosanoids |
---|
Direct Parent | Prostaglandins and related compounds |
---|
Alternative Parents | |
---|
Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Hydroxy fatty acid
- Cyclopentanol
- Fatty acid
- Unsaturated fatty acid
- Cyclic alcohol
- Secondary alcohol
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic oxide
- Organic oxygen compound
- Alcohol
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homomonocyclic compound
|
---|
Molecular Framework | Aliphatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | 4.39 | BODOR,H & HUANG,M (1992) |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Prostaglandin F2b,1TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2883.7 | Semi standard non polar | 33892256 | Prostaglandin F2b,1TMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O | 2784.6 | Semi standard non polar | 33892256 | Prostaglandin F2b,1TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O | 2765.8 | Semi standard non polar | 33892256 | Prostaglandin F2b,1TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2816.1 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2755.7 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2746.0 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2827.9 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O | 2750.7 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2762.8 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2742.2 | Semi standard non polar | 33892256 | Prostaglandin F2b,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C | 2718.1 | Semi standard non polar | 33892256 | Prostaglandin F2b,3TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2744.9 | Semi standard non polar | 33892256 | Prostaglandin F2b,3TMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2730.6 | Semi standard non polar | 33892256 | Prostaglandin F2b,3TMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C | 2713.7 | Semi standard non polar | 33892256 | Prostaglandin F2b,4TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C)C[C@@H](O[Si](C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2746.0 | Semi standard non polar | 33892256 | Prostaglandin F2b,1TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3139.4 | Semi standard non polar | 33892256 | Prostaglandin F2b,1TBDMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O | 2997.0 | Semi standard non polar | 33892256 | Prostaglandin F2b,1TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O | 2980.6 | Semi standard non polar | 33892256 | Prostaglandin F2b,1TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3080.5 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3245.1 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3232.7 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3363.9 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O | 3197.2 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TBDMS,isomer #5 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3243.4 | Semi standard non polar | 33892256 | Prostaglandin F2b,2TBDMS,isomer #6 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3227.3 | Semi standard non polar | 33892256 | Prostaglandin F2b,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3429.7 | Semi standard non polar | 33892256 | Prostaglandin F2b,3TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3490.6 | Semi standard non polar | 33892256 | Prostaglandin F2b,3TBDMS,isomer #3 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3479.2 | Semi standard non polar | 33892256 | Prostaglandin F2b,3TBDMS,isomer #4 | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C | 3432.6 | Semi standard non polar | 33892256 | Prostaglandin F2b,4TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1[C@H](O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C\CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3625.0 | Semi standard non polar | 33892256 |
|
---|